ArticleBulletin of experimental biology and medicine2025
Assessment of Specific IgE Levels to Major Allergens Fel d 1 and Can f 1 Using the AllergochipRF and ImmunoCAP Diagnostic Platforms.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed specific IgE levels to the major epidermal allergens of cat (Fel d 1) and dog (Can f 1) in 55 patients with clinically confirmed sensitization, using both the experimental microchip-based platform AllergochipRF and the reference ImmunoCAP system. A high degree of agreement was observed between the two platforms, with Spearman correlation coefficients of r = 0.94 for Fel d 1 and r = 0.85 for Can f 1 (p < 0.001). Differences in absolute specific IgE values were noted, which can be attributed to the distinct analytical principles of the platforms, particularly the upper measurement limit of ImmunoCAP and the broader dynamic signal range of AllergochipRF. These findings confirm the analytical comparability of the two methods and highlight the potential of AllergochipRF for expanded molecular diagnosis of sensitization and for monitoring the efficacy of allergen-specific immunotherapy.
Indexed as
Identifiers
41663840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.